PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC) by Samaneh Moradi, Pedram Sarikhani, Rafid Jihad Albadr, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Hiba Mushtaq, Niyousha Vakilzadehian

Subjects: Get full text

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... by Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo

Subjects: Get full text

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment by F. Rossari, D. Lavacchi, E. Alimenti, C. Soldà, F. Salani, L. Esposito, S. Foti, S. Camera, M. Persano, F. Lo Prinzi, F. Vitiello, E. Pellegrini, M. Bruccoleri, M.D. Rizzato, M. Caccese, I.G. Rapposelli, A. Guidolin, A. De Rosa, L. Antonuzzo, G. Masi, M.A. Iavarone, S. Lonardi, M. Rimini, A. Casadei-Gardini

Subjects: Get full text

Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezo... by Giulia Pasello, Giulia Pigato, Daniela Scattolin, Stefania Lando, Sara Potente, Chiara Romualdi, Anna Roma, Maria Vittoria Resi, Stefano Frega, Alessandra Ferro, Alessandro Dal Maso, Laura Bonanno, Valentina Guarneri, Elisabetta Lazzarini, Stefano Indraccolo

Subjects: Get full text

Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report by Ko Masaki, Motoyasu Miyzaki, Kota Mashima, Yasutaka Sumi, Kohei Noda, Syohei Ueno, Takashi Tanaka, Nobutaka Takahashi, Susumu Kaneshige, Hidetoshi Kamimura

Subjects: Get full text

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatm... by Federico Cappuzzo, MD, Zanete Zvirbule, MD, Ernesto Korbenfeld, MD, Jaroslaw Kolb-Sielecki, MD, Dolores Isla, MD, PhD, Aleksandra Szczesna, MD, PhD, Amparo Yovanna Castro Sanchez, PhD, Alberto Bustillos, MD, Xiaoyan Liu, PhD, Fiona Young, MbChB, Nadia Tosti, PhD, Marta Freitas Monteiro, MSc, PhD, Margarita Majem, MD, PhD

Subjects: Get full text

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis by Jie Dai, Tianxiao Xu, Lifeng Li, Meiyu Fang, Jing Lin, Jun Cao, Xue Bai, Caili Li, Xiaoting Wei, Junjie Gu, Yaoyao Liu, Xuan Gao, Xuefeng Xia, Jun Guo, Yu Chen, Lili Mao, Lu Si

Subjects: “…atezolizumab…”
Get full text

Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma by Shaobo Zhang, Zebin Zhu, Lianxin Liu, Björn Nashan, Shugeng Zhang

Subjects: Get full text

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer by Amparo Burgos-San José, Claudia Colomer-Aguilar, Daniel Martínez-Caballero, Bartomeu Massutí-Sureda

Subjects: “…atezolizumab…”
Get full text

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination wit... by Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi, Yoshitaka Inaba, Tatsuya Yamashita, Hideki Iwamoto, Makoto Ueno, Sadahisa Ogasawara, Teiji Kuzuya, Takahiro Kodama, Yozo Sato, Toshifumi Tada, Kaoru Tsuchiya, Hideyuki Nishiofuku, Koichiro Yamakado, Miyuki Sone, Masafumi Ikeda, Tetsuo Takehara, Tetsutaro Hamano, Masatoshi Kudo

Subjects: “…Atezolizumab…”
Get full text

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US by Yingtao Lin, Cijuan Li, Chang Wang, Jian Chen, Yuanqing Huang

Subjects: “…atezolizumab…”
Get full text

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy by Ryosuke Tsunemitsu, Motoyasu Tabuchi, Shinya Sakamoto, Kenta Ogi, Manabu Matsumoto, Jun Iwata, Takehiro Okabayashi

Subjects: Get full text

Brain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports by Bangju Kim, Hyun Joon Park, Sang Uk Lee, Kwang Il Seo, Jung Wook Lee, Sumin Jo, Jun Yeb Nam

Subjects: “…atezolizumab…”
Get full text

Prior corticosteroid treatment alters cPBMC composition and IFNγ response to immunotherapy in canine cancer by Anna Barbara Emilia Zimmermann, Anna Barbara Emilia Zimmermann, Betül Taskoparan, Daniel Fuchs, Daniel Fuchs, Stanislav Pantelyushin, Mathischan Maheswaran, Manuela Schnyder, Sonja Hartnack, Carla Rohrer Bley, Johannes vom Berg

Subjects: Get full text

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience by Fateen Ata, Adeel Ahmad Khan, Emad Algorani, Amr Faisal Musaed Alsharafi, Reham Abo Shdid, Mohammad Nofal, Ayman R. Ibrahim, Loai Abdullah, Khalil Youssef El Annan, Tareq Emad Hawash Al-Bkoor, Kakil Ibrahim Rasul, Tarik Elhadd, Haval Surchi

Subjects: Get full text

Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer by Juanyan Shen, Juanyan Shen, Juanyan Shen, Junliang Ma, Shaolin Chen, Su-Han Jin, Junzhu Xu, Qisha Li, Chi Zhang, Xiaojing Tian, Xiaofei Chen, Fangya Tan, Markus Hecht, Benjamin Frey, Benjamin Frey, Benjamin Frey, Udo S. Gaipl, Udo S. Gaipl, Udo S. Gaipl, Hu Ma, Jian-Guo Zhou, Jian-Guo Zhou, Jian-Guo Zhou

Subjects: Get full text

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab by Jaejun Lee, Jaejun Lee, Jae-Sung Yoo, Ji Hoon Kim, Ji Hoon Kim, Dong Yeup Lee, Keungmo Yang, Keungmo Yang, Bohyun Kim, Joon-Il Choi, Jeong Won Jang, Jeong Won Jang, Jong Young Choi, Jong Young Choi, Seung Kew Yoon, Seung Kew Yoon, Ji Won Han, Ji Won Han, Pil Soo Sung, Pil Soo Sung

Subjects: Get full text

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study by Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran

Subjects: “…atezolizumab…”
Get full text

Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC by Hee Sun Cho, Hee Sun Cho, Hee Sun Cho, Soon Kyu Lee, Soon Kyu Lee, Ji Won Han, Ji Won Han, Jung Hyun Kwon, Jung Hyun Kwon, Soon Woo Nam, Soon Woo Nam, Jaejun Lee, Jaejun Lee, Keungmo Yang, Keungmo Yang, Pil Soo Sung, Pil Soo Sung, Jeong Won Jang, Jeong Won Jang, Seung Kew Yoon, Seung Kew Yoon, Jong Young Choi, Jong Young Choi

Subjects: Get full text

Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature by Iva Skocilic, Alojzije Kosic, Ivona Badovinac, Tajana Filipec Kanizaj, Renata Dobrila Dintinjana, Maja Kolak, Anamarija Bukovica, Sanja Ropac, Ivana Mikolasevic

Subjects: “…atezolizumab…”
Get full text